Mindy Simpson to Hemophilia A
This is a "connection" page, showing publications Mindy Simpson has written about Hemophilia A.
Connection Strength
1.905
-
Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. J Thromb Haemost. 2018 04; 16(4):778-790.
Score: 0.543
-
Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018 01; 16(1):39-43.
Score: 0.265
-
Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood. 2017 10 12; 130(15):1757-1759.
Score: 0.260
-
Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood. 2017 03 09; 129(10):1245-1250.
Score: 0.249
-
Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors. Haemophilia. 2017 Nov; 23(6):844-851.
Score: 0.131
-
PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. Haemophilia. 2017 Nov; 23(6):832-843.
Score: 0.130
-
Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(?) ) in patients with severe haemophilia A. Haemophilia. 2016 Sep; 22(5):730-8.
Score: 0.121
-
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
Score: 0.120
-
Exploring the biological basis of haemophilic joint disease: experimental studies. Haemophilia. 2012 May; 18(3):310-8.
Score: 0.087